Axsome Therapeutics Inc (AXSM)
77.38
+1.45
(+1.91%)
USD |
NASDAQ |
May 16, 16:00
76.05
-1.33
(-1.72%)
After-Hours: 20:00
Axsome Therapeutics Debt to Equity Ratio: 1.241 for March 31, 2024
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
Date | Value |
---|---|
March 31, 2024 | 1.241 |
December 31, 2023 | 0.9324 |
September 30, 2023 | 0.6584 |
June 30, 2023 | 0.6342 |
Date | Value |
---|---|
March 31, 2023 | 1.320 |
December 31, 2022 | 0.8604 |
September 30, 2022 | 0.5968 |
June 30, 2022 | 6.149 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
0.5968
Minimum
Sep 2022
6.149
Maximum
Jun 2022
1.549
Average
0.8964
Median
Debt to Equity Ratio Benchmarks
Krystal Biotech Inc | 0.00 |
Catalyst Pharmaceuticals Inc | 0.00 |
Vertex Pharmaceuticals Inc | 0.00 |
Vistagen Therapeutics Inc | 0.00 |
ADMA Biologics Inc | 0.8513 |
Debt to Equity Ratio Related Metrics
Total Assets (Quarterly) | 545.73M |
Total Liabilities (Quarterly) | 401.69M |
Shareholders Equity (Quarterly) | 144.04M |
Current Ratio | 3.197 |
Net Debt Paydown Yield | -0.45% |